Melissa Avery

Statistics

Publications

Citations

2.1K

H-Index

Active since

1986

Affiliations

Pfizer (United States)(Current)

Utah State University

Melissa Avery is an author at Pfizer (United States) specializing in infectious diseases, treatment of coronavirus infections, and antiviral pharmacotherapy.

Publications per year

1986–2025

Publications

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner et al. · Journal of Medicinal Chemistry · 2024 · 73 citations · Full text

Medicine, Infectious Diseases, Pharmacology +15

Use of Crosslinked Xanthan Gels in Actual Profile Modification Field Projects

Melissa Avery, Luke Burkholder, M. Gruenenfelder · International Meeting on Petroleum Engineering · 1986 · 27 citations

Engineering, Chemical Engineering, Materials Engineering +14

An Oral SARS-CoV-2 M <sup>pro</sup> Inhibitor Clinical Candidate for the Treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · medRxiv · 2021 · 23 citations · Full text

Medicine, Infectious Diseases, Pharmacology +13

Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease

Jamison B. Tuttle, Christophe Allais, Charlotte Allerton et al. · Journal of Medicinal Chemistry · 2025 · 23 citations

Pharmacy, Infectious Diseases, Pharmacology +15

1–5 of 6